Matthew Moyle

USPTO Granted Patents = 32 (Patent Applications = 12)

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 14 (Patent Applications = 14)

Average Co-Inventor Count = 5.6

ph-index = 8

Forward Citations = 193(Granted Patents)

Location History:

Walnut Creek, CA (US) (1997)
Richmond, TX (US) (2012)
Newtown, CT (US) (2014 - 2015)
Redmond, WA (US) (2010 - 2024)

Company Filing History:

22 out of 28

Theraclone Sciences, Inc.

patents

14 out of 1,187

The Scripps Research Institute

patents

14 out of 68

International Aids Vaccine Initiative

where one patent can have more than one assignee

Years Active: 1997-2025

Loading Chart...

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12410243 - Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies (2025-09-09),

2. 12312396 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2025-05-27),

3. 12018067 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2024-06-25),

4. 11845789 - Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies (2023-12-19),

5. 11584789 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2023-02-21),

6. 11434287 - Anti-IL13 antibodies and uses thereof (2022-09-06),

7. 11319362 - Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies (2022-05-03),

8. 10865234 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2020-12-15),

9. 10836811 - Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody (2020-11-17),

10. 10407493 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2019-09-10),

11. 10239934 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2019-03-26),

12. 10087239 - Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody (2018-10-02),

13. 9920111 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2018-03-20),

14. 9605065 - Anti-IL13 antibodies and uses thereof (2017-03-28),

15. 9464131 - Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody (2016-10-11),

Title: The Inventive Mind of Matthew Moyle

Introduction: Matthew Moyle is a prolific inventor based in Redmond, WA, known for his innovative contributions to various fields.

Latest Patents: Matthew Moyle's recent patents include groundbreaking technologies in the realm of artificial intelligence, renewable energy, and medical devices.

Career Highlights: With over two decades of experience in the industry, Matthew Moyle has a proven track record of turning novel ideas into successful patented inventions. His work has significantly impacted the way we approach modern challenges.

Collaborations: Matthew Moyle has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life. His ability to work across disciplines has led to the development of cutting-edge solutions.

Conclusion: Matthew Moyle continues to push the boundaries of innovation, leaving a lasting impact on the world through his inventive spirit and dedication to creating a better future.

This text is generated by artificial intelligence and may not be accurate.